BioSpace News Archive

Veru Inc. today announced that the U.S. Food and Drug Administration (FDA) has informed the Company of an updated meeting date for the FDA’s Pulmonary-Allergy Drugs Advisory Committee to discuss the Company’s request for Emergency Use Authorization of sabizabulin.

Roche (SIX: RO, ROG; OTCQX: RHHBY) received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the cobas® pure integrated solutions, the next generation of innovation in the cobas family of Serum Work Area solutions.

JPMorgan Chase, one of the most established financial institutions in the world and the largest bank in the United States, has become a member of the Q-NEXT quantum research center.

Lyfebulb, a patient-empowerment platform that connects patients with industry experts to support user-driven innovation, and Veloxis Pharmaceuticals, a fully integrated specialty pharmaceutical company, are pleased to announce 10 finalists for the 2022 “Transforming Organ Transplantation Through Innovation” Challenge.

Pulse Healthcare System (Pulse) today announced that they have entered into a definitive agreement to acquire a controlling interest in Crystal Outpatient Surgery Center (Crystal ASC).

Baudax Bio, Inc. announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series B Preferred Stock, par value $0.01 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 p.m. Eastern Time on September 29, 2022.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), today announced the closing of its public offering of 4,800,000 shares of its common stock at a public offering price of $26.00 per share on September 19, 2022.

Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced it has entered into a strategic partnership and exclusive license agreement with DRS Daylight Solutions to expand the use of mid-infrared (mid-IR) technology in the bioprocessing market.

Virios Therapeutics, Inc., a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced that it intends to offer to sell shares of its common stock in an underwritten public offering.

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare cannabinoids, will report financial results on Friday, September 23, 2022 for the fiscal year ended June 30, 2022.